Posttransplantation diabetes - A systematic review of the literature

被引:443
作者
Montori, VM
Basu, A
Erwin, PJ
Velosa, JA
Gabriel, SE
Kudva, YC
机构
[1] Mayo Clin, Div Endocrinol Diabet Metab Nutr & Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin, Med Lib, Rochester, MN USA
[3] Mayo Clin, Div Nephrol & Internal Med, Rochester, MN USA
[4] Mayo Clin, Transplant Ctr, Rochester, MN USA
[5] Mayo Clin, Clin Epidemiol Sect, Rochester, MN USA
关键词
D O I
10.2337/diacare.25.3.583
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To systematically the incidence of posttransplantation diabetes (PTD) risk factors for its development. prognostic implications, and optimal management RESEARCH DESIGN AND METHODS - We searched databases, (MEDLINE, EMBASE, the Cochrane Library, and others) from Inception to September 2000, reviewed bibliographies in reports retrieved, contacted transplantation experts, and reviewed specialty journals Two reviewers independently determined report inclusion (original studies, in all languages, of PTD in adults with no history of diabetes before transplantation), assessed study methods, and extracted data using a standardized form. Meta-regression as used to explain between-study differences in incidence. RESULTS - Nineteen studies with 3,611 patients were included The 12-month cumulative incidence of PTD is lower (<10% in most studies) than it was 3 decades ago, The type of immunosuppression explained 74% of the variability in incidence (P = 0.0004). Risk factors were patient age, nonwhite ethnicity, glucocorticoid treatment for rejection, and immunosuppression with high-close cyclosporine and tacrolimus. PTD was associated with decreased graft and patient survival in earlier studies later studies showed improved outcomes. Randomized trials of treatment regimens have not been conducted. CONCLUSIONS - Physicians should consider modification of immunosuppressive regimens to decrease the risk of PTD in high-risk transplant recipients Randomized trials are needed to evaluate the use of oral glucose-lowering agents in transplant recipients, paying particular attention to interactions with immunosuppressive drugs.
引用
收藏
页码:583 / 592
页数:10
相关论文
共 80 条
[1]  
AHN KJ, 1992, TRANSPLANT P, V24, P1581
[2]   Cardiovascular risk factors and diseases after renal transplantation [J].
Aker S. ;
Ivens K. ;
Grabensee B. ;
Heering P. .
International Urology and Nephrology, 1998, 30 (6) :777-788
[3]   CLINICAL-TRIAL OF FK-506 IMMUNOSUPPRESSION IN ADULT CARDIAC TRANSPLANTATION [J].
ARMITAGE, JM ;
KORMOS, RL ;
MORITA, S ;
FUNG, J ;
MARRONE, GC ;
HARDESTY, RL ;
GRIFFITH, BP ;
STARZL, TE ;
BOLMAN, RM ;
COOPER, JD ;
BHAUANA, JN .
ANNALS OF THORACIC SURGERY, 1992, 54 (02) :205-211
[4]   SOME CHARACTERISTICS OF STEROID DIABETES - A STUDY IN RENAL-TRANSPLANT RECIPIENTS RECEIVING HIGH-DOSE CORTICOSTEROID-THERAPY [J].
ARNER, P ;
GUNNARSSON, R ;
BLOMDAHL, S ;
GROTH, CG .
DIABETES CARE, 1983, 6 (01) :23-25
[5]  
BASRI N, 1992, TRANSPLANT P, V24, P1780
[6]   INVITED COMMENTARY - BENEFITS OF HETEROGENEITY IN METAANALYSIS OF DATA FROM EPIDEMIOLOGIC STUDIES [J].
BERLIN, JA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 142 (04) :383-387
[7]   THE IMPACT OF CYCLOSPORINE AND COMBINATION IMMUNOSUPPRESSION ON THE INCIDENCE OF POSTTRANSPLANT DIABETES IN RENAL-ALLOGRAFT RECIPIENTS [J].
BOUDREAUX, JP ;
MCHUGH, L ;
CANAFAX, DM ;
ASCHER, N ;
SUTHERLAND, DER ;
PAYNE, W ;
SIMMONS, RL ;
NAJARIAN, JS ;
FRYD, DS .
TRANSPLANTATION, 1987, 44 (03) :376-381
[8]  
BOUDREAUX JP, 1987, TRANSPLANT P, V19, P1811
[9]  
CARROLL PB, 1991, TRANSPLANT P, V23, P337
[10]   Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation [J].
Cavaille-Coll, MW ;
Elashoff, MR .
TRANSPLANTATION, 1998, 65 (01) :142-144